Cognito Therapeutics has delivered clinical data from its digital treatment for patients with Alzheimer’s disease—which relies on light and sound to stimulate specific electrical frequencies ...

Yesterday Cognito Therapeutics, a startup using visual and auditory stimulation to treat neurodegenerative disorders, announced Phase 2 trial results suggesting its gamma frequency neuromodulation ...

Alzheimer’s disease research at MIT spawned Cognito Therapeutics, a startup whose medical device uses light and sound to modulate electrical activity that supports brain health. The company’s ...

Cognito Therapeutics has spent the better part of the last decade developing neuromodulation technology that it claims could stop and even reverse the progression of Alzheimer’s and other ...

Cognito’s OVERTURE trial demonstrated significant ‘time saved’ in functional and cognitive decline at both six and 18 months.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a pioneer in non-invasive optogenetics to treat neurodegenerative diseases, announced today the appointment of Jennifer Newberger as Vice ...

Cognito to Present Phase 2 OVERTURE Study Open-Label Extension Data Showing Safety and Durability of Treatment Benefits Over 18 Months at CTAD 2023 ...

CAMBRIDGE, Mass., July 17, 2025--Cognito Therapeutics to Present Five Abstracts at AAIC 2025 Highlighting Spectris™ Treatment in Alzheimer’s Disease ...

HOPE is evaluating Cognito’s investigative non-invasive neuroprotective therapy to better preserve cognition and function in patients with Alzheimer’s. The study is the largest ever medical ...